Biodistribution of cisplatin revealed by imaging mass cytometry identifies extensive collagen binding in tumor and normal tissues
Authors:
Open Access
- 4 November 2016
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 36641
Abstract
Imaging mass cytometry was used for direct visualization of platinum localization in tissue sections from tumor and normal tissues of cisplatin-treated mice bearing pancreas cancer patient-derived xenografts. This recently-developed technology enabled simultaneous detection of multiple markers to define cell lineage, DNA damage response, cell proliferation and functional state, providing a highly detailed view of drug incorporation in tumor and normal tissues at the cellular level. A striking and unanticipated finding was the extensive binding of platinum to collagen fibers in both tumor and normal mouse tissues. Time course experiments indicated the slow release of stroma-bound platinum, although it is currently unclear if released platinum retains biological activity. Imaging mass cytometry offers a unique window into the in vivo effects of platinum compounds, and it is likely that this can be extended into the clinic in order to optimize the use of this important class of agent.Keywords
This publication has 35 references indexed in Scilit:
- Subcellular targets of cisplatin cytotoxicity: An integrated viewPharmacology & Therapeutics, 2012
- Associations Between ABCC2 Polymorphisms and Cisplatin Disposition and EfficacyClinical Pharmacology & Therapeutics, 2012
- Impact of Long-Term Serum Platinum Concentrations on Neuro- and Ototoxicity in Cisplatin-Treated Survivors of Testicular CancerJournal of Clinical Oncology, 2012
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic ContinuumScience, 2011
- Long-term platinum retention after treatment with cisplatin and oxaliplatinBMC Clinical Pharmacology, 2008
- Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nucleiNucleic Acids Research, 2006
- Toxic Injury to Hepatic Sinusoids: Sinusoidal Obstruction Syndrome (Veno-Occlusive Disease)Seminars in Liver Disease, 2002
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNABiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1985